Journal Article Review Epublish 37 citations
PubMed: 36866275 DOI: 10.3389/fcell.2023.1116805
Epigenetic reprogramming in cancer: From diagnosis to treatment.
Front Cell Dev Biol 11:1116805
Authors: Pedro Mikael da Silva Costa, Sarah Leyenne Alves Sales, Daniel Pascoalino Pinheiro, Larissa Queiroz Pontes, Sarah Sant'Anna Maranhão, Claudia do Ó Pessoa, Gilvan Pessoa Furtado, Cristiana Libardi Miranda Furtado
Affiliations
- Department of Physiology and Pharmacology, Drug Research and Development Center, Federal University of Ceará, Fortaleza, Ceará, Brazil.
- Postgraduation Program in Biotechnology Northeastern Network of Biotechnology, Federal University of Ceará, Fortaleza, Ceará, Brazil.
- Postgraduation Program in Pharmacology, Federal University of Ceará, Fortaleza, Ceará, Brazil.
- Oswaldo Cruz Foundation, FIOCRUZ-Ceará, Sector of Biotechnology, Eusebio, Ceará, Brazil.
- Postgraduation Program in Biotechnology and Natural Resources, Federal University of Ceará, Fortaleza, Ceará, Brazil.
- Drug Research and Development Center, Postgraduate Program in Translational Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.
- Experimental Biology Center, University of Fortaleza, Fortaleza, Ceará, Brazil.
Abstract
Disruption of the epigenetic program of gene expression is a hallmark of cancer that initiates and propagates tumorigenesis. Altered DNA methylation, histone modifications and ncRNAs expression are a feature of cancer cells. The dynamic epigenetic changes during oncogenic transformation are related to tumor heterogeneity, unlimited self-renewal and multi-lineage differentiation. This stem cell-like state or the aberrant reprogramming of cancer stem cells is the major challenge in treatment and drug resistance. Given the reversible nature of epigenetic modifications, the ability to restore the cancer epigenome through the inhibition of the epigenetic modifiers is a promising therapy for cancer treatment, either as a monotherapy or in combination with other anticancer therapies, including immunotherapies. Herein, we highlighted the main epigenetic alterations, their potential as a biomarker for early diagnosis and the epigenetic therapies approved for cancer treatment.
MeSH
Diagnosis, Stem Cells, Therapeutics, Neoplasms, Microscopy, Electron, Scanning Transmission, Genes
Cited by
- Transforming Growth Factor-β Pathway: Biological Functions and Therapeutic Targets. MedComm (2020), 2025
- Integrative Analysis Reveals the Prognostic Effects of Epigenetic Regulators in Bladder Cancer. Cancer Med, 2025
- Promising new drugs and therapeutic approaches for treatment of ovarian cancer-targeting the hallmarks of cancer. BMC Med, 2025
- Epigenetic modifications in breast cancer: from immune escape mechanisms to therapeutic target discovery. Front Immunol, 2025
- Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice. Cancers (Basel), 2024
- Chemical catalyst manipulating cancer epigenome and transcription. Nat Commun, 2025
- Transcription of Endogenous Retroviruses: Broad and Precise Mechanisms of Control. Viruses, 2024
- Epigenetic regulation of reprogramming and pluripotency: insights from histone modifications and their implications for cancer stem cell therapies. Front Cell Dev Biol, 2025
- Cellular Epigenetic Targets and Epidrugs in Breast Cancer Therapy: Mechanisms, Challenges, and Future Perspectives. Pharmaceuticals (Basel), 2025
- Current Research in Drug-Free Cancer Therapies. Bioengineering (Basel), 2025
- Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer. Front Immunol, 2025
- The Roles of H3K9me3 Writers, Readers, and Erasers in Cancer Immunotherapy. Int J Mol Sci, 2024
- Epigenomic Echoes-Decoding Genomic and Epigenetic Instability to Distinguish Lung Cancer Types and Predict Relapse. Epigenomes, 2025
- Post-Translational Modifications of Proteins Orchestrate All Hallmarks of Cancer. Life (Basel), 2025